401k Plan data: BACTOLAC PHARMACEUTICAL 401(K) PLAN plan

BACTOLAC PHARMACEUTICAL 401(K) PLAN 401k Plan overview

Plan Name	BACTOLAC PHARMACEUTICAL 401(K) PLAN
Plan identification number	001

BACTOLAC PHARMACEUTICAL 401(K) PLAN Benefits

401k Plan Type

Defined Contribution Pension

Plan Features/Benefits

Profit-sharing
ERISA section 404(c) Plan - This plan, or any part of it is intended to meet the conditions of 29 CFR 2550.404c-1.
Total participant-directed account plan - Participants have the opportunity to direct the investment of all the assets allocated to their individual accounts, regardless of whether 29 CFR 2550.404c-1 is intended to be met.
Code section 401(k) feature - A cash or deferred arrangement described in Code section 401(k) that is part of a qualified defined contribution plan that provides for an election by employees to defer part of their compensation or receive these amounts in cash.
Code section 401(m) arrangement - Employee contributions are allocated to separate accounts under the plan or employer contributions are based, in whole or in part, on employee deferrals or contribtions to the plan. Not applicable if plan is 401(k) plan with only QNECs and/or QMACs. Also not applicable if Code section 403(b)(1), 403(b)(7) or 408 arrangements/accounts/annuities.
Total or partial participant-directed account plan - plan uses default investment account for participants who fail to direct assets in their account.
Master plan - A pension plan that is made available by a sponsor for adoption by employers; that is the subject of a favorable opinion letter; and for which a single funding medium (for example, a trust or custodial account) is established for the joint use of all adopting employers.
Plan sponsor(s) is (are) a member(s) of a controlled group (Code sections 414(b), (c), or (m)).

401k Sponsoring company profile

BACTOLAC PHARMACEUTICAL, INC. has sponsored the creation of one or more 401k plans.

Company Name: BACTOLAC PHARMACEUTICAL, INC.

Employer identification number (EIN): 113259533

NAIC Classification: 325410

Additional information about BACTOLAC PHARMACEUTICAL, INC.

Jurisdiction of Incorporation: State of Delaware Division of Corporations

Incorporation Date:

Company Identification Number: 2929493

More information about BACTOLAC PHARMACEUTICAL, INC.

Form 5500 Filing Information

Submission information for form 5500 for 401k plan BACTOLAC PHARMACEUTICAL 401(K) PLAN

Plan id# Filing Submission Date Name of Administrator Date Administrator Signed Name of Company Sponsor Date Sponsor Signed
001 2021-07-01
001 2020-07-01
001 2019-07-01
001 2018-07-01
001 2017-07-01
001 2016-07-01 RENEE REYNOLDS RENEE REYNOLDS 2018-03-29
001 2015-07-01 RENEE REYNOLDS RENEE REYNOLDS 2017-03-31
001 2014-07-01 RENEE REYNOLDS RENEE REYNOLDS 2016-04-04
001 2013-07-01 RENEE REYNOLDS RENEE REYNOLDS 2015-04-07
001 2012-07-01 RENEE REYNOLDS RENEE REYNOLDS 2014-04-08
001 2011-07-01 RENEE REYNOLDS
001 2010-07-01 RENEE REYNOLDS
001 2009-07-01 RENEE REYNOLDS

Plan id#	Filing Submission Date	Name of Administrator	Name of Company Sponsor	Date Sponsor Signed
001	2021-07-01
001	2020-07-01
001	2019-07-01
001	2018-07-01
001	2017-07-01
001	2016-07-01	RENEE REYNOLDS	RENEE REYNOLDS	2018-03-29
001	2015-07-01	RENEE REYNOLDS	RENEE REYNOLDS	2017-03-31
001	2014-07-01	RENEE REYNOLDS	RENEE REYNOLDS	2016-04-04
001	2013-07-01	RENEE REYNOLDS	RENEE REYNOLDS	2015-04-07
001	2012-07-01	RENEE REYNOLDS	RENEE REYNOLDS	2014-04-08
001	2011-07-01	RENEE REYNOLDS
001	2010-07-01	RENEE REYNOLDS
001	2009-07-01	RENEE REYNOLDS

Plan Statistics for BACTOLAC PHARMACEUTICAL 401(K) PLAN

401k plan membership statisitcs for BACTOLAC PHARMACEUTICAL 401(K) PLAN

Measure Date Value
2021: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2021 401k membership
Total participants, beginning-of-year 2021-07-01 695
Total number of active participants reported on line 7a of the Form 5500 2021-07-01 637
Number of retired or separated participants receiving benefits 2021-07-01 0
Number of other retired or separated participants entitled to future benefits 2021-07-01 44
Total of all active and inactive participants 2021-07-01 681
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2021-07-01 0
Total participants 2021-07-01 681
Number of participants with account balances 2021-07-01 327
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2021-07-01 16
2020: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2020 401k membership
Total participants, beginning-of-year 2020-07-01 701
Total number of active participants reported on line 7a of the Form 5500 2020-07-01 663
Number of retired or separated participants receiving benefits 2020-07-01 0
Number of other retired or separated participants entitled to future benefits 2020-07-01 32
Total of all active and inactive participants 2020-07-01 695
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2020-07-01 0
Total participants 2020-07-01 695
Number of participants with account balances 2020-07-01 333
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2020-07-01 14
2019: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2019 401k membership
Total participants, beginning-of-year 2019-07-01 894
Total number of active participants reported on line 7a of the Form 5500 2019-07-01 637
Number of retired or separated participants receiving benefits 2019-07-01 0
Number of other retired or separated participants entitled to future benefits 2019-07-01 63
Total of all active and inactive participants 2019-07-01 700
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2019-07-01 1
Total participants 2019-07-01 701
Number of participants with account balances 2019-07-01 365
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2019-07-01 14
2018: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2018 401k membership
Total participants, beginning-of-year 2018-07-01 764
Total number of active participants reported on line 7a of the Form 5500 2018-07-01 846
Number of retired or separated participants receiving benefits 2018-07-01 0
Number of other retired or separated participants entitled to future benefits 2018-07-01 48
Total of all active and inactive participants 2018-07-01 894
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2018-07-01 0
Total participants 2018-07-01 894
Number of participants with account balances 2018-07-01 336
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2018-07-01 14
2017: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2017 401k membership
Total participants, beginning-of-year 2017-07-01 748
Total number of active participants reported on line 7a of the Form 5500 2017-07-01 728
Number of retired or separated participants receiving benefits 2017-07-01 0
Number of other retired or separated participants entitled to future benefits 2017-07-01 36
Total of all active and inactive participants 2017-07-01 764
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2017-07-01 0
Total participants 2017-07-01 764
Number of participants with account balances 2017-07-01 282
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2017-07-01 15
2016: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2016 401k membership
Total participants, beginning-of-year 2016-07-01 664
Total number of active participants reported on line 7a of the Form 5500 2016-07-01 726
Number of retired or separated participants receiving benefits 2016-07-01 0
Number of other retired or separated participants entitled to future benefits 2016-07-01 22
Total of all active and inactive participants 2016-07-01 748
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2016-07-01 0
Total participants 2016-07-01 748
Number of participants with account balances 2016-07-01 213
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2016-07-01 11
2015: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2015 401k membership
Total participants, beginning-of-year 2015-07-01 598
Total number of active participants reported on line 7a of the Form 5500 2015-07-01 654
Number of retired or separated participants receiving benefits 2015-07-01 0
Number of other retired or separated participants entitled to future benefits 2015-07-01 9
Total of all active and inactive participants 2015-07-01 663
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2015-07-01 1
Total participants 2015-07-01 664
Number of participants with account balances 2015-07-01 155
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2015-07-01 3
2014: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2014 401k membership
Total participants, beginning-of-year 2014-07-01 535
Total number of active participants reported on line 7a of the Form 5500 2014-07-01 587
Number of retired or separated participants receiving benefits 2014-07-01 0
Number of other retired or separated participants entitled to future benefits 2014-07-01 10
Total of all active and inactive participants 2014-07-01 597
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2014-07-01 1
Total participants 2014-07-01 598
Number of participants with account balances 2014-07-01 88
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2014-07-01 2
2013: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2013 401k membership
Total participants, beginning-of-year 2013-07-01 459
Total number of active participants reported on line 7a of the Form 5500 2013-07-01 528
Number of retired or separated participants receiving benefits 2013-07-01 0
Number of other retired or separated participants entitled to future benefits 2013-07-01 6
Total of all active and inactive participants 2013-07-01 534
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2013-07-01 1
Total participants 2013-07-01 535
Number of participants with account balances 2013-07-01 57
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2013-07-01 0
2012: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2012 401k membership
Total participants, beginning-of-year 2012-07-01 474
Total number of active participants reported on line 7a of the Form 5500 2012-07-01 452
Number of retired or separated participants receiving benefits 2012-07-01 0
Number of other retired or separated participants entitled to future benefits 2012-07-01 6
Total of all active and inactive participants 2012-07-01 458
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2012-07-01 1
Total participants 2012-07-01 459
Number of participants with account balances 2012-07-01 51
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2012-07-01 0
2011: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2011 401k membership
Total participants, beginning-of-year 2011-07-01 390
Total number of active participants reported on line 7a of the Form 5500 2011-07-01 469
Number of retired or separated participants receiving benefits 2011-07-01 0
Number of other retired or separated participants entitled to future benefits 2011-07-01 4
Total of all active and inactive participants 2011-07-01 473
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2011-07-01 1
Total participants 2011-07-01 474
Number of participants with account balances 2011-07-01 45
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2011-07-01 1
2010: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2010 401k membership
Total participants, beginning-of-year 2010-07-01 195
Total number of active participants reported on line 7a of the Form 5500 2010-07-01 382
Number of retired or separated participants receiving benefits 2010-07-01 0
Number of other retired or separated participants entitled to future benefits 2010-07-01 3
Total of all active and inactive participants 2010-07-01 385
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2010-07-01 1
Total participants 2010-07-01 386
Number of participants with account balances 2010-07-01 38
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2010-07-01 0
2009: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2009 401k membership
Total participants, beginning-of-year 2009-07-01 197
Total number of active participants reported on line 7a of the Form 5500 2009-07-01 192
Number of retired or separated participants receiving benefits 2009-07-01 0
Number of other retired or separated participants entitled to future benefits 2009-07-01 3
Total of all active and inactive participants 2009-07-01 195
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits 2009-07-01 0
Total participants 2009-07-01 195
Number of participants with account balances 2009-07-01 32
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested 2009-07-01 0

Measure	Date	Value
2021: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2021 401k membership
Total participants, beginning-of-year	2021-07-01	695
Total number of active participants reported on line 7a of the Form 5500	2021-07-01	637
Number of retired or separated participants receiving benefits	2021-07-01	0
Number of other retired or separated participants entitled to future benefits	2021-07-01	44
Total of all active and inactive participants	2021-07-01	681
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2021-07-01	0
Total participants	2021-07-01	681
Number of participants with account balances	2021-07-01	327
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2021-07-01	16
2020: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2020 401k membership
Total participants, beginning-of-year	2020-07-01	701
Total number of active participants reported on line 7a of the Form 5500	2020-07-01	663
Number of retired or separated participants receiving benefits	2020-07-01	0
Number of other retired or separated participants entitled to future benefits	2020-07-01	32
Total of all active and inactive participants	2020-07-01	695
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2020-07-01	0
Total participants	2020-07-01	695
Number of participants with account balances	2020-07-01	333
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2020-07-01	14
2019: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2019 401k membership
Total participants, beginning-of-year	2019-07-01	894
Total number of active participants reported on line 7a of the Form 5500	2019-07-01	637
Number of retired or separated participants receiving benefits	2019-07-01	0
Number of other retired or separated participants entitled to future benefits	2019-07-01	63
Total of all active and inactive participants	2019-07-01	700
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2019-07-01	1
Total participants	2019-07-01	701
Number of participants with account balances	2019-07-01	365
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2019-07-01	14
2018: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2018 401k membership
Total participants, beginning-of-year	2018-07-01	764
Total number of active participants reported on line 7a of the Form 5500	2018-07-01	846
Number of retired or separated participants receiving benefits	2018-07-01	0
Number of other retired or separated participants entitled to future benefits	2018-07-01	48
Total of all active and inactive participants	2018-07-01	894
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2018-07-01	0
Total participants	2018-07-01	894
Number of participants with account balances	2018-07-01	336
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2018-07-01	14
2017: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2017 401k membership
Total participants, beginning-of-year	2017-07-01	748
Total number of active participants reported on line 7a of the Form 5500	2017-07-01	728
Number of retired or separated participants receiving benefits	2017-07-01	0
Number of other retired or separated participants entitled to future benefits	2017-07-01	36
Total of all active and inactive participants	2017-07-01	764
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2017-07-01	0
Total participants	2017-07-01	764
Number of participants with account balances	2017-07-01	282
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2017-07-01	15
2016: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2016 401k membership
Total participants, beginning-of-year	2016-07-01	664
Total number of active participants reported on line 7a of the Form 5500	2016-07-01	726
Number of retired or separated participants receiving benefits	2016-07-01	0
Number of other retired or separated participants entitled to future benefits	2016-07-01	22
Total of all active and inactive participants	2016-07-01	748
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2016-07-01	0
Total participants	2016-07-01	748
Number of participants with account balances	2016-07-01	213
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2016-07-01	11
2015: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2015 401k membership
Total participants, beginning-of-year	2015-07-01	598
Total number of active participants reported on line 7a of the Form 5500	2015-07-01	654
Number of retired or separated participants receiving benefits	2015-07-01	0
Number of other retired or separated participants entitled to future benefits	2015-07-01	9
Total of all active and inactive participants	2015-07-01	663
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2015-07-01	1
Total participants	2015-07-01	664
Number of participants with account balances	2015-07-01	155
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2015-07-01	3
2014: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2014 401k membership
Total participants, beginning-of-year	2014-07-01	535
Total number of active participants reported on line 7a of the Form 5500	2014-07-01	587
Number of retired or separated participants receiving benefits	2014-07-01	0
Number of other retired or separated participants entitled to future benefits	2014-07-01	10
Total of all active and inactive participants	2014-07-01	597
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2014-07-01	1
Total participants	2014-07-01	598
Number of participants with account balances	2014-07-01	88
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2014-07-01	2
2013: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2013 401k membership
Total participants, beginning-of-year	2013-07-01	459
Total number of active participants reported on line 7a of the Form 5500	2013-07-01	528
Number of retired or separated participants receiving benefits	2013-07-01	0
Number of other retired or separated participants entitled to future benefits	2013-07-01	6
Total of all active and inactive participants	2013-07-01	534
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2013-07-01	1
Total participants	2013-07-01	535
Number of participants with account balances	2013-07-01	57
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2013-07-01	0
2012: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2012 401k membership
Total participants, beginning-of-year	2012-07-01	474
Total number of active participants reported on line 7a of the Form 5500	2012-07-01	452
Number of retired or separated participants receiving benefits	2012-07-01	0
Number of other retired or separated participants entitled to future benefits	2012-07-01	6
Total of all active and inactive participants	2012-07-01	458
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2012-07-01	1
Total participants	2012-07-01	459
Number of participants with account balances	2012-07-01	51
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2012-07-01	0
2011: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2011 401k membership
Total participants, beginning-of-year	2011-07-01	390
Total number of active participants reported on line 7a of the Form 5500	2011-07-01	469
Number of retired or separated participants receiving benefits	2011-07-01	0
Number of other retired or separated participants entitled to future benefits	2011-07-01	4
Total of all active and inactive participants	2011-07-01	473
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2011-07-01	1
Total participants	2011-07-01	474
Number of participants with account balances	2011-07-01	45
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2011-07-01	1
2010: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2010 401k membership
Total participants, beginning-of-year	2010-07-01	195
Total number of active participants reported on line 7a of the Form 5500	2010-07-01	382
Number of retired or separated participants receiving benefits	2010-07-01	0
Number of other retired or separated participants entitled to future benefits	2010-07-01	3
Total of all active and inactive participants	2010-07-01	385
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2010-07-01	1
Total participants	2010-07-01	386
Number of participants with account balances	2010-07-01	38
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2010-07-01	0
2009: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2009 401k membership
Total participants, beginning-of-year	2009-07-01	197
Total number of active participants reported on line 7a of the Form 5500	2009-07-01	192
Number of retired or separated participants receiving benefits	2009-07-01	0
Number of other retired or separated participants entitled to future benefits	2009-07-01	3
Total of all active and inactive participants	2009-07-01	195
Number of deceased participants whose beneficiaries are receiving or are entitled to receive benefits	2009-07-01	0
Total participants	2009-07-01	195
Number of participants with account balances	2009-07-01	32
Participants that terminated employment during the plan year with accrued benefits that were less than 100% vested	2009-07-01	0

Financial Data on BACTOLAC PHARMACEUTICAL 401(K) PLAN

Measure	Date	Value
2022 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2022 401k financial data
Unrealized appreciation/depreciation of real estate assets	2022-06-30	$0
Unrealized appreciation/depreciation of other (non real estate) assets	2022-06-30	$0
Total unrealized appreciation/depreciation of assets	2022-06-30	$0
Total transfer of assets to this plan	2022-06-30	$0
Total transfer of assets from this plan	2022-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2022-06-30	$59,690
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2022-06-30	$0
Expenses. Interest paid	2022-06-30	$0
Amount of participant contributions which was failed to transmit to the plan within the time period described in 29 CFR 251.3-102	2022-06-30	$0
Total income from all sources (including contributions)	2022-06-30	$265,165
Total loss/gain on sale of assets	2022-06-30	$0
Total of all expenses incurred	2022-06-30	$565,541
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2022-06-30	$373,407
Expenses. Certain deemed distributions of participant loans	2022-06-30	$947
Value of total corrective distributions	2022-06-30	$109,667
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2022-06-30	$1,412,917
Value of total assets at end of year	2022-06-30	$6,533,051
Value of total assets at beginning of year	2022-06-30	$6,773,737
Total of administrative expenses incurred including professional, contract, advisory and management fees	2022-06-30	$81,520
Total income from rents	2022-06-30	$0
Total interest from all sources	2022-06-30	$13,402
Total dividends received (eg from common stock, registered investment company shares)	2022-06-30	$279,871
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2022-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2022-06-30	$279,871
Assets. Real estate other than employer real property at end of year	2022-06-30	$0
Assets. Real estate other than employer real property at beginning of year	2022-06-30	$0
Administrative expenses professional fees incurred	2022-06-30	$0
Assets. Corporate prefeered stocks other than exployer securities at end of year	2022-06-30	$0
Assets. Corporate prefeered stocks other than exployer securities at beginning of year	2022-06-30	$0
Was this plan covered by a fidelity bond	2022-06-30	Yes
Value of fidelity bond cover	2022-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2022-06-30	No
Were there any nonexempt tranactions with any party-in-interest	2022-06-30	No
Contributions received from participants	2022-06-30	$1,260,654
Participant contributions at end of year	2022-06-30	$240,415
Participant contributions at beginning of year	2022-06-30	$72,073
Participant contributions at end of year	2022-06-30	$0
Participant contributions at beginning of year	2022-06-30	$0
Assets. Other investments not covered elsewhere at end of year	2022-06-30	$0
Assets. Other investments not covered elsewhere at beginning of year	2022-06-30	$0
Income. Received or receivable in cash from other sources (including rollovers)	2022-06-30	$38,685
Expenses. Other payments made (not to insurance carriers or or participants/beneficiaries)	2022-06-30	$0
Value of other receiveables (less allowance for doubtful accounts) at end of year	2022-06-30	$0
Value of other receiveables (less allowance for doubtful accounts) at beginning of year	2022-06-30	$0
Assets. Loans (other than to participants) at end of year	2022-06-30	$0
Assets. Loans (other than to participants) at beginning of year	2022-06-30	$0
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year	2022-06-30	$59,690
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year	2022-06-30	$0
Other income not declared elsewhere	2022-06-30	$0
Administrative expenses (other) incurred	2022-06-30	$81,194
Liabilities. Value of operating payables at end of year	2022-06-30	$0
Liabilities. Value of operating payables at beginning of year	2022-06-30	$0
Total non interest bearing cash at end of year	2022-06-30	$0
Total non interest bearing cash at beginning of year	2022-06-30	$0
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2022-06-30	No
Income. Non cash contributions	2022-06-30	$0
Value of net income/loss	2022-06-30	$-300,376
Value of net assets at end of year (total assets less liabilities)	2022-06-30	$6,473,361
Value of net assets at beginning of year (total assets less liabilities)	2022-06-30	$6,773,737
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2022-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2022-06-30	No
Were any leases to which the plan was party in default or uncollectible	2022-06-30	No
Assets. partnership/joint venture interests at end of year	2022-06-30	$0
Assets. partnership/joint venture interests at beginning of year	2022-06-30	$0
Investment advisory and management fees	2022-06-30	$326
Value of interest in registered invesment companies (eg mutual funds) at end of year	2022-06-30	$5,717,907
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2022-06-30	$6,089,464
Value of interest in pooled separate accounts at end of year	2022-06-30	$0
Value of interest in pooled separate accounts at beginning of year	2022-06-30	$0
Interest on participant loans	2022-06-30	$6,084
Income. Interest from loans (other than to participants)	2022-06-30	$0
Interest earned on other investments	2022-06-30	$7,318
Income. Interest from US Government securities	2022-06-30	$0
Income. Interest from corporate debt instruments	2022-06-30	$0
Value of interest in master investment trust accounts at end of year	2022-06-30	$0
Value of interest in master investment trust accounts at beginning of year	2022-06-30	$0
Value of interest in common/collective trusts at end of year	2022-06-30	$39,882
Value of interest in common/collective trusts at beginning of year	2022-06-30	$100,296
Value of interest bearing cash (including money market accounts and certificates of deposits) at end of year	2022-06-30	$36
Interest-bearing cash (include money market accounts & certificates of deposit) at beginning of the Year	2022-06-30	$37
Value of interest bearing cash (including money market accounts and certificates of deposits) at beginning of year	2022-06-30	$37
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2022-06-30	$0
Assets. Value of investments in 103.12 investment entities at end of year	2022-06-30	$0
Assets. Value of investments in 103.12 investment entities at beginning of year	2022-06-30	$0
Value of funds held in insurance company general accounts (unallocated contracts) at end of year	2022-06-30	$534,811
Value of funds held in insurance company general accounts (unallocated contracts) at beginning of year	2022-06-30	$511,867
Expenses. Payments to insurance carriers foe the provision of benefits	2022-06-30	$0
Asset value of US Government securities at end of year	2022-06-30	$0
Asset value of US Government securities at beginning of year	2022-06-30	$0
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2022-06-30	$-1,415,792
Net investment gain/loss from pooled separate accounts	2022-06-30	$0
Net investment gain or loss from common/collective trusts	2022-06-30	$-25,233
Net gain/loss from 103.12 investment entities	2022-06-30	$0
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2022-06-30	No
Was there a failure to transmit to the plan any participant contributions	2022-06-30	No
Has the plan failed to provide any benefit when due under the plan	2022-06-30	No
Assets. Invements in employer securities at end of year	2022-06-30	$0
Assets. Invements in employer securities at beginning of year	2022-06-30	$0
Assets. Value of employer real property at end of year	2022-06-30	$0
Assets. Value of employer real property at beginning of year	2022-06-30	$0
Contributions received in cash from employer	2022-06-30	$113,578
Employer contributions (assets) at end of year	2022-06-30	$0
Employer contributions (assets) at beginning of year	2022-06-30	$0
Income. Dividends from preferred stock	2022-06-30	$0
Income. Dividends from common stock	2022-06-30	$0
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2022-06-30	$373,407
Asset. Corporate debt instrument preferred debt at end of year	2022-06-30	$0
Asset. Corporate debt instrument preferred debt at beginning of year	2022-06-30	$0
Asset. Corporate debt instrument debt (other) at end of year	2022-06-30	$0
Asset. Corporate debt instrument debt (other) at beginning of year	2022-06-30	$0
Contract administrator fees	2022-06-30	$0
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3	2022-06-30	No
Assets. Corporate common stocks other than exployer securities at end of year	2022-06-30	$0
Assets. Corporate common stocks other than exployer securities at beginning of year	2022-06-30	$0
Liabilities. Value of benefit claims payable at end of year	2022-06-30	$0
Liabilities. Value of benefit claims payable at beginning of year	2022-06-30	$0
Assets. Value of buildings and other operty used in plan operation at end of year	2022-06-30	$0
Assets. Value of buildings and other operty used in plan operation at beginning of year	2022-06-30	$0
Did the plan have assets held for investment	2022-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2022-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2022-06-30	No
Aggregate proceeds on sale of assets	2022-06-30	$0
Aggregate carrying amount (costs) on sale of assets	2022-06-30	$0
Liabilities. Value of acquisition indebtedness at end of year	2022-06-30	$0
Liabilities. Value of acquisition indebtedness at beginning of year	2022-06-30	$0
Opinion of an independent qualified public accountant for this plan	2022-06-30	Unqualified
Accountancy firm name	2022-06-30	MARCUM LLP
Accountancy firm EIN	2022-06-30	111986323
2021 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2021 401k financial data
Unrealized appreciation/depreciation of real estate assets	2021-06-30	$0
Unrealized appreciation/depreciation of other (non real estate) assets	2021-06-30	$0
Total unrealized appreciation/depreciation of assets	2021-06-30	$0
Total transfer of assets to this plan	2021-06-30	$0
Total transfer of assets from this plan	2021-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2021-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2021-06-30	$0
Expenses. Interest paid	2021-06-30	$0
Amount of participant contributions which was failed to transmit to the plan within the time period described in 29 CFR 251.3-102	2021-06-30	$0
Total income from all sources (including contributions)	2021-06-30	$2,779,525
Total loss/gain on sale of assets	2021-06-30	$0
Total of all expenses incurred	2021-06-30	$583,480
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2021-06-30	$489,530
Expenses. Certain deemed distributions of participant loans	2021-06-30	$0
Value of total corrective distributions	2021-06-30	$27,066
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2021-06-30	$1,239,332
Value of total assets at end of year	2021-06-30	$6,773,737
Value of total assets at beginning of year	2021-06-30	$4,577,692
Total of administrative expenses incurred including professional, contract, advisory and management fees	2021-06-30	$66,884
Total income from rents	2021-06-30	$0
Total interest from all sources	2021-06-30	$3,039
Total dividends received (eg from common stock, registered investment company shares)	2021-06-30	$154,527
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2021-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2021-06-30	$154,527
Assets. Real estate other than employer real property at end of year	2021-06-30	$0
Assets. Real estate other than employer real property at beginning of year	2021-06-30	$0
Administrative expenses professional fees incurred	2021-06-30	$0
Assets. Corporate prefeered stocks other than exployer securities at end of year	2021-06-30	$0
Assets. Corporate prefeered stocks other than exployer securities at beginning of year	2021-06-30	$0
Was this plan covered by a fidelity bond	2021-06-30	Yes
Value of fidelity bond cover	2021-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2021-06-30	No
Were there any nonexempt tranactions with any party-in-interest	2021-06-30	No
Contributions received from participants	2021-06-30	$1,109,049
Participant contributions at end of year	2021-06-30	$72,073
Participant contributions at beginning of year	2021-06-30	$0
Participant contributions at end of year	2021-06-30	$0
Participant contributions at beginning of year	2021-06-30	$0
Assets. Other investments not covered elsewhere at end of year	2021-06-30	$0
Assets. Other investments not covered elsewhere at beginning of year	2021-06-30	$0
Income. Received or receivable in cash from other sources (including rollovers)	2021-06-30	$16,124
Expenses. Other payments made (not to insurance carriers or or participants/beneficiaries)	2021-06-30	$0
Value of other receiveables (less allowance for doubtful accounts) at end of year	2021-06-30	$0
Value of other receiveables (less allowance for doubtful accounts) at beginning of year	2021-06-30	$0
Assets. Loans (other than to participants) at end of year	2021-06-30	$0
Assets. Loans (other than to participants) at beginning of year	2021-06-30	$0
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year	2021-06-30	$0
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year	2021-06-30	$0
Other income not declared elsewhere	2021-06-30	$0
Administrative expenses (other) incurred	2021-06-30	$66,769
Liabilities. Value of operating payables at end of year	2021-06-30	$0
Liabilities. Value of operating payables at beginning of year	2021-06-30	$0
Total non interest bearing cash at end of year	2021-06-30	$0
Total non interest bearing cash at beginning of year	2021-06-30	$0
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2021-06-30	No
Income. Non cash contributions	2021-06-30	$0
Value of net income/loss	2021-06-30	$2,196,045
Value of net assets at end of year (total assets less liabilities)	2021-06-30	$6,773,737
Value of net assets at beginning of year (total assets less liabilities)	2021-06-30	$4,577,692
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2021-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2021-06-30	No
Were any leases to which the plan was party in default or uncollectible	2021-06-30	No
Assets. partnership/joint venture interests at end of year	2021-06-30	$0
Assets. partnership/joint venture interests at beginning of year	2021-06-30	$0
Investment advisory and management fees	2021-06-30	$115
Value of interest in registered invesment companies (eg mutual funds) at end of year	2021-06-30	$6,089,464
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2021-06-30	$4,001,705
Value of interest in pooled separate accounts at end of year	2021-06-30	$0
Value of interest in pooled separate accounts at beginning of year	2021-06-30	$0
Interest on participant loans	2021-06-30	$474
Income. Interest from loans (other than to participants)	2021-06-30	$0
Interest earned on other investments	2021-06-30	$2,565
Income. Interest from US Government securities	2021-06-30	$0
Income. Interest from corporate debt instruments	2021-06-30	$0
Value of interest in master investment trust accounts at end of year	2021-06-30	$0
Value of interest in master investment trust accounts at beginning of year	2021-06-30	$0
Value of interest in common/collective trusts at end of year	2021-06-30	$100,296
Value of interest in common/collective trusts at beginning of year	2021-06-30	$575,952
Value of interest bearing cash (including money market accounts and certificates of deposits) at end of year	2021-06-30	$37
Interest-bearing cash (include money market accounts & certificates of deposit) at beginning of the Year	2021-06-30	$35
Value of interest bearing cash (including money market accounts and certificates of deposits) at beginning of year	2021-06-30	$35
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2021-06-30	$0
Assets. Value of investments in 103.12 investment entities at end of year	2021-06-30	$0
Assets. Value of investments in 103.12 investment entities at beginning of year	2021-06-30	$0
Value of funds held in insurance company general accounts (unallocated contracts) at end of year	2021-06-30	$511,867
Value of funds held in insurance company general accounts (unallocated contracts) at beginning of year	2021-06-30	$0
Expenses. Payments to insurance carriers foe the provision of benefits	2021-06-30	$0
Asset value of US Government securities at end of year	2021-06-30	$0
Asset value of US Government securities at beginning of year	2021-06-30	$0
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2021-06-30	$1,351,212
Net investment gain/loss from pooled separate accounts	2021-06-30	$0
Net investment gain or loss from common/collective trusts	2021-06-30	$31,415
Net gain/loss from 103.12 investment entities	2021-06-30	$0
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2021-06-30	No
Was there a failure to transmit to the plan any participant contributions	2021-06-30	No
Has the plan failed to provide any benefit when due under the plan	2021-06-30	No
Assets. Invements in employer securities at end of year	2021-06-30	$0
Assets. Invements in employer securities at beginning of year	2021-06-30	$0
Assets. Value of employer real property at end of year	2021-06-30	$0
Assets. Value of employer real property at beginning of year	2021-06-30	$0
Contributions received in cash from employer	2021-06-30	$114,159
Employer contributions (assets) at end of year	2021-06-30	$0
Employer contributions (assets) at beginning of year	2021-06-30	$0
Income. Dividends from preferred stock	2021-06-30	$0
Income. Dividends from common stock	2021-06-30	$0
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2021-06-30	$489,530
Asset. Corporate debt instrument preferred debt at end of year	2021-06-30	$0
Asset. Corporate debt instrument preferred debt at beginning of year	2021-06-30	$0
Asset. Corporate debt instrument debt (other) at end of year	2021-06-30	$0
Asset. Corporate debt instrument debt (other) at beginning of year	2021-06-30	$0
Contract administrator fees	2021-06-30	$0
Assets. Corporate common stocks other than exployer securities at end of year	2021-06-30	$0
Assets. Corporate common stocks other than exployer securities at beginning of year	2021-06-30	$0
Liabilities. Value of benefit claims payable at end of year	2021-06-30	$0
Liabilities. Value of benefit claims payable at beginning of year	2021-06-30	$0
Assets. Value of buildings and other operty used in plan operation at end of year	2021-06-30	$0
Assets. Value of buildings and other operty used in plan operation at beginning of year	2021-06-30	$0
Did the plan have assets held for investment	2021-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2021-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2021-06-30	No
Aggregate proceeds on sale of assets	2021-06-30	$0
Aggregate carrying amount (costs) on sale of assets	2021-06-30	$0
Liabilities. Value of acquisition indebtedness at end of year	2021-06-30	$0
Liabilities. Value of acquisition indebtedness at beginning of year	2021-06-30	$0
Opinion of an independent qualified public accountant for this plan	2021-06-30	Disclaimer
Accountancy firm name	2021-06-30	RAICH ENDE MALTER & CO, LLP
Accountancy firm EIN	2021-06-30	112336434
2020 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2020 401k financial data
Unrealized appreciation/depreciation of real estate assets	2020-06-30	$0
Unrealized appreciation/depreciation of other (non real estate) assets	2020-06-30	$0
Total unrealized appreciation/depreciation of assets	2020-06-30	$0
Total transfer of assets to this plan	2020-06-30	$0
Total transfer of assets from this plan	2020-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2020-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2020-06-30	$0
Expenses. Interest paid	2020-06-30	$0
Amount of participant contributions which was failed to transmit to the plan within the time period described in 29 CFR 251.3-102	2020-06-30	$0
Total income from all sources (including contributions)	2020-06-30	$1,218,310
Total loss/gain on sale of assets	2020-06-30	$0
Total of all expenses incurred	2020-06-30	$185,334
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2020-06-30	$107,110
Expenses. Certain deemed distributions of participant loans	2020-06-30	$0
Value of total corrective distributions	2020-06-30	$31,358
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2020-06-30	$1,130,448
Value of total assets at end of year	2020-06-30	$4,577,692
Value of total assets at beginning of year	2020-06-30	$3,544,716
Total of administrative expenses incurred including professional, contract, advisory and management fees	2020-06-30	$46,866
Total income from rents	2020-06-30	$0
Total interest from all sources	2020-06-30	$0
Total dividends received (eg from common stock, registered investment company shares)	2020-06-30	$145,746
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2020-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2020-06-30	$145,746
Assets. Real estate other than employer real property at end of year	2020-06-30	$0
Assets. Real estate other than employer real property at beginning of year	2020-06-30	$0
Administrative expenses professional fees incurred	2020-06-30	$0
Assets. Corporate prefeered stocks other than exployer securities at end of year	2020-06-30	$0
Assets. Corporate prefeered stocks other than exployer securities at beginning of year	2020-06-30	$0
Was this plan covered by a fidelity bond	2020-06-30	Yes
Value of fidelity bond cover	2020-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2020-06-30	Yes
Were there any nonexempt tranactions with any party-in-interest	2020-06-30	No
Contributions received from participants	2020-06-30	$917,941
Participant contributions at end of year	2020-06-30	$0
Participant contributions at beginning of year	2020-06-30	$0
Participant contributions at end of year	2020-06-30	$0
Participant contributions at beginning of year	2020-06-30	$0
Assets. Other investments not covered elsewhere at end of year	2020-06-30	$0
Assets. Other investments not covered elsewhere at beginning of year	2020-06-30	$0
Income. Received or receivable in cash from other sources (including rollovers)	2020-06-30	$104,777
Expenses. Other payments made (not to insurance carriers or or participants/beneficiaries)	2020-06-30	$0
Value of other receiveables (less allowance for doubtful accounts) at end of year	2020-06-30	$0
Value of other receiveables (less allowance for doubtful accounts) at beginning of year	2020-06-30	$0
Assets. Loans (other than to participants) at end of year	2020-06-30	$0
Assets. Loans (other than to participants) at beginning of year	2020-06-30	$0
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at end of year	2020-06-30	$0
Other liabilities (not benefit claims, operating payabales oe acquisition indebtedness) at beginning of year	2020-06-30	$0
Other income not declared elsewhere	2020-06-30	$3,603
Administrative expenses (other) incurred	2020-06-30	$46,853
Liabilities. Value of operating payables at end of year	2020-06-30	$0
Liabilities. Value of operating payables at beginning of year	2020-06-30	$0
Total non interest bearing cash at end of year	2020-06-30	$0
Total non interest bearing cash at beginning of year	2020-06-30	$0
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2020-06-30	No
Income. Non cash contributions	2020-06-30	$0
Value of net income/loss	2020-06-30	$1,032,976
Value of net assets at end of year (total assets less liabilities)	2020-06-30	$4,577,692
Value of net assets at beginning of year (total assets less liabilities)	2020-06-30	$3,544,716
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2020-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2020-06-30	No
Were any leases to which the plan was party in default or uncollectible	2020-06-30	No
Assets. partnership/joint venture interests at end of year	2020-06-30	$0
Assets. partnership/joint venture interests at beginning of year	2020-06-30	$0
Investment advisory and management fees	2020-06-30	$13
Value of interest in registered invesment companies (eg mutual funds) at end of year	2020-06-30	$4,001,705
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2020-06-30	$2,958,070
Value of interest in pooled separate accounts at end of year	2020-06-30	$0
Value of interest in pooled separate accounts at beginning of year	2020-06-30	$0
Interest on participant loans	2020-06-30	$0
Income. Interest from loans (other than to participants)	2020-06-30	$0
Interest earned on other investments	2020-06-30	$0
Income. Interest from US Government securities	2020-06-30	$0
Income. Interest from corporate debt instruments	2020-06-30	$0
Value of interest in master investment trust accounts at end of year	2020-06-30	$0
Value of interest in master investment trust accounts at beginning of year	2020-06-30	$0
Value of interest in common/collective trusts at end of year	2020-06-30	$575,952
Value of interest in common/collective trusts at beginning of year	2020-06-30	$586,646
Value of interest bearing cash (including money market accounts and certificates of deposits) at end of year	2020-06-30	$35
Interest-bearing cash (include money market accounts & certificates of deposit) at beginning of the Year	2020-06-30	$0
Value of interest bearing cash (including money market accounts and certificates of deposits) at beginning of year	2020-06-30	$0
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2020-06-30	$0
Assets. Value of investments in 103.12 investment entities at end of year	2020-06-30	$0
Assets. Value of investments in 103.12 investment entities at beginning of year	2020-06-30	$0
Value of funds held in insurance company general accounts (unallocated contracts) at end of year	2020-06-30	$0
Value of funds held in insurance company general accounts (unallocated contracts) at beginning of year	2020-06-30	$0
Expenses. Payments to insurance carriers foe the provision of benefits	2020-06-30	$0
Asset value of US Government securities at end of year	2020-06-30	$0
Asset value of US Government securities at beginning of year	2020-06-30	$0
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2020-06-30	$-78,349
Net investment gain/loss from pooled separate accounts	2020-06-30	$0
Net investment gain or loss from common/collective trusts	2020-06-30	$16,862
Net gain/loss from 103.12 investment entities	2020-06-30	$0
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2020-06-30	No
Was there a failure to transmit to the plan any participant contributions	2020-06-30	No
Has the plan failed to provide any benefit when due under the plan	2020-06-30	No
Assets. Invements in employer securities at end of year	2020-06-30	$0
Assets. Invements in employer securities at beginning of year	2020-06-30	$0
Assets. Value of employer real property at end of year	2020-06-30	$0
Assets. Value of employer real property at beginning of year	2020-06-30	$0
Contributions received in cash from employer	2020-06-30	$107,730
Employer contributions (assets) at end of year	2020-06-30	$0
Employer contributions (assets) at beginning of year	2020-06-30	$0
Income. Dividends from preferred stock	2020-06-30	$0
Income. Dividends from common stock	2020-06-30	$0
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2020-06-30	$107,110
Asset. Corporate debt instrument preferred debt at end of year	2020-06-30	$0
Asset. Corporate debt instrument preferred debt at beginning of year	2020-06-30	$0
Asset. Corporate debt instrument debt (other) at end of year	2020-06-30	$0
Asset. Corporate debt instrument debt (other) at beginning of year	2020-06-30	$0
Contract administrator fees	2020-06-30	$0
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3	2020-06-30	Yes
Assets. Corporate common stocks other than exployer securities at end of year	2020-06-30	$0
Assets. Corporate common stocks other than exployer securities at beginning of year	2020-06-30	$0
Liabilities. Value of benefit claims payable at end of year	2020-06-30	$0
Liabilities. Value of benefit claims payable at beginning of year	2020-06-30	$0
Assets. Value of buildings and other operty used in plan operation at end of year	2020-06-30	$0
Assets. Value of buildings and other operty used in plan operation at beginning of year	2020-06-30	$0
Did the plan have assets held for investment	2020-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2020-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2020-06-30	No
Aggregate proceeds on sale of assets	2020-06-30	$0
Aggregate carrying amount (costs) on sale of assets	2020-06-30	$0
Liabilities. Value of acquisition indebtedness at end of year	2020-06-30	$0
Liabilities. Value of acquisition indebtedness at beginning of year	2020-06-30	$0
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2020-06-30	Yes
Opinion of an independent qualified public accountant for this plan	2020-06-30	Disclaimer
Accountancy firm name	2020-06-30	RAICH ENDE MALTER & CO, LLP
Accountancy firm EIN	2020-06-30	112336434
2019 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2019 401k financial data
Total unrealized appreciation/depreciation of assets	2019-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2019-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2019-06-30	$0
Total income from all sources (including contributions)	2019-06-30	$1,141,461
Total loss/gain on sale of assets	2019-06-30	$0
Total of all expenses incurred	2019-06-30	$179,757
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2019-06-30	$129,856
Value of total corrective distributions	2019-06-30	$14,641
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2019-06-30	$971,019
Value of total assets at end of year	2019-06-30	$3,544,716
Value of total assets at beginning of year	2019-06-30	$2,583,012
Total of administrative expenses incurred including professional, contract, advisory and management fees	2019-06-30	$35,260
Total interest from all sources	2019-06-30	$0
Total dividends received (eg from common stock, registered investment company shares)	2019-06-30	$22,930
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2019-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2019-06-30	$22,930
Was this plan covered by a fidelity bond	2019-06-30	Yes
Value of fidelity bond cover	2019-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2019-06-30	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2019-06-30	$0
Were there any nonexempt tranactions with any party-in-interest	2019-06-30	No
Contributions received from participants	2019-06-30	$836,960
Income. Received or receivable in cash from other sources (including rollovers)	2019-06-30	$34,212
Other income not declared elsewhere	2019-06-30	$1
Administrative expenses (other) incurred	2019-06-30	$35,260
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2019-06-30	No
Value of net income/loss	2019-06-30	$961,704
Value of net assets at end of year (total assets less liabilities)	2019-06-30	$3,544,716
Value of net assets at beginning of year (total assets less liabilities)	2019-06-30	$2,583,012
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2019-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2019-06-30	No
Were any leases to which the plan was party in default or uncollectible	2019-06-30	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2019-06-30	$2,958,070
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2019-06-30	$2,178,056
Value of interest in common/collective trusts at end of year	2019-06-30	$586,646
Value of interest in common/collective trusts at beginning of year	2019-06-30	$404,956
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2019-06-30	$137,047
Net investment gain or loss from common/collective trusts	2019-06-30	$10,464
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2019-06-30	No
Was there a failure to transmit to the plan any participant contributions	2019-06-30	No
Has the plan failed to provide any benefit when due under the plan	2019-06-30	No
Contributions received in cash from employer	2019-06-30	$99,847
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2019-06-30	$129,856
Did the plan have assets held for investment	2019-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2019-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2019-06-30	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2019-06-30	Yes
Opinion of an independent qualified public accountant for this plan	2019-06-30	Disclaimer
Accountancy firm name	2019-06-30	RAICH ENDE MALTER & CO, LLP
Accountancy firm EIN	2019-06-30	112336434
2018 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2018 401k financial data
Total unrealized appreciation/depreciation of assets	2018-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2018-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2018-06-30	$0
Total income from all sources (including contributions)	2018-06-30	$943,745
Total loss/gain on sale of assets	2018-06-30	$0
Total of all expenses incurred	2018-06-30	$196,909
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2018-06-30	$157,652
Value of total corrective distributions	2018-06-30	$11,870
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2018-06-30	$770,983
Value of total assets at end of year	2018-06-30	$2,583,012
Value of total assets at beginning of year	2018-06-30	$1,836,176
Total of administrative expenses incurred including professional, contract, advisory and management fees	2018-06-30	$27,387
Total interest from all sources	2018-06-30	$0
Total dividends received (eg from common stock, registered investment company shares)	2018-06-30	$16,460
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2018-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2018-06-30	$16,460
Was this plan covered by a fidelity bond	2018-06-30	Yes
Value of fidelity bond cover	2018-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2018-06-30	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2018-06-30	$0
Were there any nonexempt tranactions with any party-in-interest	2018-06-30	No
Contributions received from participants	2018-06-30	$676,042
Income. Received or receivable in cash from other sources (including rollovers)	2018-06-30	$12,130
Administrative expenses (other) incurred	2018-06-30	$27,387
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2018-06-30	No
Value of net income/loss	2018-06-30	$746,836
Value of net assets at end of year (total assets less liabilities)	2018-06-30	$2,583,012
Value of net assets at beginning of year (total assets less liabilities)	2018-06-30	$1,836,176
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2018-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2018-06-30	No
Were any leases to which the plan was party in default or uncollectible	2018-06-30	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2018-06-30	$2,178,056
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2018-06-30	$1,514,066
Value of interest in common/collective trusts at end of year	2018-06-30	$404,956
Value of interest in common/collective trusts at beginning of year	2018-06-30	$322,110
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2018-06-30	$149,141
Net investment gain or loss from common/collective trusts	2018-06-30	$7,161
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2018-06-30	No
Was there a failure to transmit to the plan any participant contributions	2018-06-30	No
Has the plan failed to provide any benefit when due under the plan	2018-06-30	No
Contributions received in cash from employer	2018-06-30	$82,811
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2018-06-30	$157,652
Did the plan have assets held for investment	2018-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2018-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2018-06-30	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2018-06-30	Yes
Opinion of an independent qualified public accountant for this plan	2018-06-30	Disclaimer
Accountancy firm name	2018-06-30	RAICH ENDE MALTER & CO., LLP
Accountancy firm EIN	2018-06-30	112336434
2017 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2017 401k financial data
Total unrealized appreciation/depreciation of assets	2017-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2017-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2017-06-30	$0
Total income from all sources (including contributions)	2017-06-30	$854,539
Total loss/gain on sale of assets	2017-06-30	$0
Total of all expenses incurred	2017-06-30	$143,671
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2017-06-30	$95,439
Value of total corrective distributions	2017-06-30	$28,370
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2017-06-30	$662,846
Value of total assets at end of year	2017-06-30	$1,836,176
Value of total assets at beginning of year	2017-06-30	$1,125,308
Total of administrative expenses incurred including professional, contract, advisory and management fees	2017-06-30	$19,862
Total interest from all sources	2017-06-30	$0
Total dividends received (eg from common stock, registered investment company shares)	2017-06-30	$10,771
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2017-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2017-06-30	$10,771
Was this plan covered by a fidelity bond	2017-06-30	Yes
Value of fidelity bond cover	2017-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2017-06-30	No
Were there any nonexempt tranactions with any party-in-interest	2017-06-30	No
Contributions received from participants	2017-06-30	$495,083
Income. Received or receivable in cash from other sources (including rollovers)	2017-06-30	$104,117
Administrative expenses (other) incurred	2017-06-30	$19,862
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2017-06-30	No
Value of net income/loss	2017-06-30	$710,868
Value of net assets at end of year (total assets less liabilities)	2017-06-30	$1,836,176
Value of net assets at beginning of year (total assets less liabilities)	2017-06-30	$1,125,308
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2017-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2017-06-30	No
Were any leases to which the plan was party in default or uncollectible	2017-06-30	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2017-06-30	$1,514,066
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2017-06-30	$825,197
Value of interest in common/collective trusts at end of year	2017-06-30	$322,110
Value of interest in common/collective trusts at beginning of year	2017-06-30	$300,111
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2017-06-30	$175,386
Net investment gain or loss from common/collective trusts	2017-06-30	$5,536
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2017-06-30	No
Was there a failure to transmit to the plan any participant contributions	2017-06-30	No
Has the plan failed to provide any benefit when due under the plan	2017-06-30	No
Contributions received in cash from employer	2017-06-30	$63,646
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2017-06-30	$95,439
Did the plan have assets held for investment	2017-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2017-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2017-06-30	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2017-06-30	Yes
Opinion of an independent qualified public accountant for this plan	2017-06-30	Disclaimer
Accountancy firm name	2017-06-30	RAICH ENDE MALTER & CO LLP
Accountancy firm EIN	2017-06-30	112336434
2016 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2016 401k financial data
Total unrealized appreciation/depreciation of assets	2016-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2016-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2016-06-30	$0
Total income from all sources (including contributions)	2016-06-30	$384,197
Total loss/gain on sale of assets	2016-06-30	$0
Total of all expenses incurred	2016-06-30	$208,264
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2016-06-30	$158,130
Expenses. Certain deemed distributions of participant loans	2016-06-30	$0
Value of total corrective distributions	2016-06-30	$33,639
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2016-06-30	$390,832
Value of total assets at end of year	2016-06-30	$1,125,308
Value of total assets at beginning of year	2016-06-30	$949,375
Total of administrative expenses incurred including professional, contract, advisory and management fees	2016-06-30	$16,495
Total interest from all sources	2016-06-30	$0
Total dividends received (eg from common stock, registered investment company shares)	2016-06-30	$2,363
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2016-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2016-06-30	$2,363
Was this plan covered by a fidelity bond	2016-06-30	Yes
Value of fidelity bond cover	2016-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2016-06-30	Yes
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2016-06-30	$0
Were there any nonexempt tranactions with any party-in-interest	2016-06-30	No
Contributions received from participants	2016-06-30	$348,506
Other income not declared elsewhere	2016-06-30	$4
Administrative expenses (other) incurred	2016-06-30	$16,495
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2016-06-30	No
Value of net income/loss	2016-06-30	$175,933
Value of net assets at end of year (total assets less liabilities)	2016-06-30	$1,125,308
Value of net assets at beginning of year (total assets less liabilities)	2016-06-30	$949,375
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2016-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2016-06-30	No
Were any leases to which the plan was party in default or uncollectible	2016-06-30	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2016-06-30	$825,197
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2016-06-30	$342,528
Value of interest in common/collective trusts at end of year	2016-06-30	$300,111
Value of interest in common/collective trusts at beginning of year	2016-06-30	$606,847
Expenses. Payments to insurance carriers foe the provision of benefits	2016-06-30	$0
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2016-06-30	$-18,103
Net investment gain or loss from common/collective trusts	2016-06-30	$9,101
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2016-06-30	No
Was there a failure to transmit to the plan any participant contributions	2016-06-30	No
Has the plan failed to provide any benefit when due under the plan	2016-06-30	No
Contributions received in cash from employer	2016-06-30	$42,326
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2016-06-30	$158,130
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3	2016-06-30	Yes
Did the plan have assets held for investment	2016-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2016-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2016-06-30	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2016-06-30	Yes
Opinion of an independent qualified public accountant for this plan	2016-06-30	Disclaimer
Accountancy firm name	2016-06-30	RAICH ENDE MALTER & CO LLP
Accountancy firm EIN	2016-06-30	112336434
2015 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2015 401k financial data
Total unrealized appreciation/depreciation of assets	2015-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2015-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2015-06-30	$0
Total income from all sources (including contributions)	2015-06-30	$327,688
Total loss/gain on sale of assets	2015-06-30	$0
Total of all expenses incurred	2015-06-30	$141,301
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2015-06-30	$122,416
Value of total corrective distributions	2015-06-30	$7,594
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2015-06-30	$307,223
Value of total assets at end of year	2015-06-30	$949,375
Value of total assets at beginning of year	2015-06-30	$762,988
Total of administrative expenses incurred including professional, contract, advisory and management fees	2015-06-30	$11,291
Total interest from all sources	2015-06-30	$0
Total dividends received (eg from common stock, registered investment company shares)	2015-06-30	$23,244
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2015-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2015-06-30	$23,244
Was this plan covered by a fidelity bond	2015-06-30	Yes
Value of fidelity bond cover	2015-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2015-06-30	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2015-06-30	$0
Were there any nonexempt tranactions with any party-in-interest	2015-06-30	No
Contributions received from participants	2015-06-30	$261,423
Income. Received or receivable in cash from other sources (including rollovers)	2015-06-30	$21,453
Other income not declared elsewhere	2015-06-30	$9
Administrative expenses (other) incurred	2015-06-30	$11,291
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2015-06-30	No
Value of net income/loss	2015-06-30	$186,387
Value of net assets at end of year (total assets less liabilities)	2015-06-30	$949,375
Value of net assets at beginning of year (total assets less liabilities)	2015-06-30	$762,988
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2015-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2015-06-30	No
Were any leases to which the plan was party in default or uncollectible	2015-06-30	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2015-06-30	$342,528
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2015-06-30	$391,072
Value of interest in common/collective trusts at end of year	2015-06-30	$606,847
Value of interest in common/collective trusts at beginning of year	2015-06-30	$371,916
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2015-06-30	$-10,208
Net investment gain or loss from common/collective trusts	2015-06-30	$7,420
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2015-06-30	No
Was there a failure to transmit to the plan any participant contributions	2015-06-30	No
Has the plan failed to provide any benefit when due under the plan	2015-06-30	No
Contributions received in cash from employer	2015-06-30	$24,347
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2015-06-30	$122,416
Did the plan have assets held for investment	2015-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2015-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2015-06-30	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2015-06-30	Yes
Opinion of an independent qualified public accountant for this plan	2015-06-30	Disclaimer
Accountancy firm name	2015-06-30	RAICH ENDE MALTER & CO. LLP
Accountancy firm EIN	2015-06-30	112336434
2014 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2014 401k financial data
Total unrealized appreciation/depreciation of assets	2014-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2014-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2014-06-30	$0
Total income from all sources (including contributions)	2014-06-30	$258,083
Total loss/gain on sale of assets	2014-06-30	$0
Total of all expenses incurred	2014-06-30	$46,003
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2014-06-30	$27,639
Value of total corrective distributions	2014-06-30	$7,624
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2014-06-30	$187,446
Value of total assets at end of year	2014-06-30	$762,988
Value of total assets at beginning of year	2014-06-30	$550,908
Total of administrative expenses incurred including professional, contract, advisory and management fees	2014-06-30	$10,740
Total interest from all sources	2014-06-30	$0
Total dividends received (eg from common stock, registered investment company shares)	2014-06-30	$17,264
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2014-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2014-06-30	$17,264
Was this plan covered by a fidelity bond	2014-06-30	Yes
Value of fidelity bond cover	2014-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2014-06-30	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2014-06-30	$0
Were there any nonexempt tranactions with any party-in-interest	2014-06-30	No
Contributions received from participants	2014-06-30	$172,345
Other income not declared elsewhere	2014-06-30	$-5
Administrative expenses (other) incurred	2014-06-30	$10,740
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2014-06-30	No
Value of net income/loss	2014-06-30	$212,080
Value of net assets at end of year (total assets less liabilities)	2014-06-30	$762,988
Value of net assets at beginning of year (total assets less liabilities)	2014-06-30	$550,908
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2014-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2014-06-30	No
Were any leases to which the plan was party in default or uncollectible	2014-06-30	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2014-06-30	$391,072
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2014-06-30	$252,764
Value of interest in common/collective trusts at end of year	2014-06-30	$371,916
Value of interest in common/collective trusts at beginning of year	2014-06-30	$298,144
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2014-06-30	$46,084
Net investment gain or loss from common/collective trusts	2014-06-30	$7,294
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2014-06-30	No
Was there a failure to transmit to the plan any participant contributions	2014-06-30	No
Has the plan failed to provide any benefit when due under the plan	2014-06-30	No
Contributions received in cash from employer	2014-06-30	$15,101
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2014-06-30	$27,639
Did the plan have assets held for investment	2014-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2014-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2014-06-30	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2014-06-30	Yes
Opinion of an independent qualified public accountant for this plan	2014-06-30	Disclaimer
Accountancy firm name	2014-06-30	RAICH ENDE MALTER & CO. LLP
Accountancy firm EIN	2014-06-30	112336434
2013 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2013 401k financial data
Unrealized appreciation/depreciation of other (non real estate) assets	2013-06-30	$-66
Total unrealized appreciation/depreciation of assets	2013-06-30	$-66
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2013-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2013-06-30	$0
Total income from all sources (including contributions)	2013-06-30	$186,973
Total loss/gain on sale of assets	2013-06-30	$0
Total of all expenses incurred	2013-06-30	$24,503
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2013-06-30	$16,620
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2013-06-30	$144,139
Value of total assets at end of year	2013-06-30	$550,908
Value of total assets at beginning of year	2013-06-30	$388,438
Total of administrative expenses incurred including professional, contract, advisory and management fees	2013-06-30	$7,883
Total interest from all sources	2013-06-30	$0
Total dividends received (eg from common stock, registered investment company shares)	2013-06-30	$7,515
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2013-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2013-06-30	$7,515
Was this plan covered by a fidelity bond	2013-06-30	Yes
Value of fidelity bond cover	2013-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2013-06-30	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2013-06-30	$0
Were there any nonexempt tranactions with any party-in-interest	2013-06-30	No
Contributions received from participants	2013-06-30	$131,487
Other income not declared elsewhere	2013-06-30	$-2
Administrative expenses (other) incurred	2013-06-30	$7,883
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2013-06-30	No
Value of net income/loss	2013-06-30	$162,470
Value of net assets at end of year (total assets less liabilities)	2013-06-30	$550,908
Value of net assets at beginning of year (total assets less liabilities)	2013-06-30	$388,438
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2013-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2013-06-30	No
Were any leases to which the plan was party in default or uncollectible	2013-06-30	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2013-06-30	$252,764
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2013-06-30	$155,979
Value of interest in common/collective trusts at end of year	2013-06-30	$298,144
Value of interest in common/collective trusts at beginning of year	2013-06-30	$232,459
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2013-06-30	$29,661
Net investment gain or loss from common/collective trusts	2013-06-30	$5,726
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2013-06-30	No
Was there a failure to transmit to the plan any participant contributions	2013-06-30	No
Has the plan failed to provide any benefit when due under the plan	2013-06-30	No
Contributions received in cash from employer	2013-06-30	$12,652
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2013-06-30	$16,620
Did the plan have assets held for investment	2013-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2013-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2013-06-30	No
Aggregate proceeds on sale of assets	2013-06-30	$2
Aggregate carrying amount (costs) on sale of assets	2013-06-30	$2
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2013-06-30	Yes
Opinion of an independent qualified public accountant for this plan	2013-06-30	Disclaimer
Accountancy firm name	2013-06-30	RAICH ENDE MALTER & CO LLP
Accountancy firm EIN	2013-06-30	112336434
2012 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2012 401k financial data
Unrealized appreciation/depreciation of other (non real estate) assets	2012-06-30	$0
Total unrealized appreciation/depreciation of assets	2012-06-30	$0
Total transfer of assets to this plan	2012-06-30	$0
Total transfer of assets from this plan	2012-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2012-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2012-06-30	$0
Total income from all sources (including contributions)	2012-06-30	$115,051
Total loss/gain on sale of assets	2012-06-30	$0
Total of all expenses incurred	2012-06-30	$4,489
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2012-06-30	$51
Expenses. Certain deemed distributions of participant loans	2012-06-30	$0
Value of total corrective distributions	2012-06-30	$0
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2012-06-30	$112,089
Value of total assets at end of year	2012-06-30	$388,438
Value of total assets at beginning of year	2012-06-30	$277,876
Total of administrative expenses incurred including professional, contract, advisory and management fees	2012-06-30	$4,438
Total interest from all sources	2012-06-30	$0
Total dividends received (eg from common stock, registered investment company shares)	2012-06-30	$660
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2012-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2012-06-30	$660
Was this plan covered by a fidelity bond	2012-06-30	Yes
Value of fidelity bond cover	2012-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2012-06-30	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2012-06-30	$0
Were there any nonexempt tranactions with any party-in-interest	2012-06-30	No
Contributions received from participants	2012-06-30	$101,154
Income. Received or receivable in cash from other sources (including rollovers)	2012-06-30	$0
Other income not declared elsewhere	2012-06-30	$640
Administrative expenses (other) incurred	2012-06-30	$4,438
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2012-06-30	No
Value of net income/loss	2012-06-30	$110,562
Value of net assets at end of year (total assets less liabilities)	2012-06-30	$388,438
Value of net assets at beginning of year (total assets less liabilities)	2012-06-30	$277,876
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2012-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2012-06-30	No
Were any leases to which the plan was party in default or uncollectible	2012-06-30	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2012-06-30	$155,979
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2012-06-30	$105,536
Interest on participant loans	2012-06-30	$0
Value of interest in common/collective trusts at end of year	2012-06-30	$232,459
Value of interest in common/collective trusts at beginning of year	2012-06-30	$172,340
Interest earned from interest bearing cash (including money market accounts and certificates of deposit)	2012-06-30	$0
Expenses. Payments to insurance carriers foe the provision of benefits	2012-06-30	$0
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2012-06-30	$-3,180
Net investment gain or loss from common/collective trusts	2012-06-30	$4,842
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2012-06-30	No
Was there a failure to transmit to the plan any participant contributions	2012-06-30	No
Has the plan failed to provide any benefit when due under the plan	2012-06-30	No
Contributions received in cash from employer	2012-06-30	$10,935
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2012-06-30	$51
Did the plan have assets held for investment	2012-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2012-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2012-06-30	No
Aggregate proceeds on sale of assets	2012-06-30	$0
Aggregate carrying amount (costs) on sale of assets	2012-06-30	$0
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2012-06-30	Yes
Opinion of an independent qualified public accountant for this plan	2012-06-30	Disclaimer
Accountancy firm name	2012-06-30	RAICH ENDE MALTER & CO LLP
Accountancy firm EIN	2012-06-30	112336434
2011 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2011 401k financial data
Total unrealized appreciation/depreciation of assets	2011-06-30	$0
Total transfer of assets to this plan	2011-06-30	$0
Total transfer of assets from this plan	2011-06-30	$0
Total liabilities at end of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2011-06-30	$0
Total liabilities at beginning of year (benefit claims payable, operating payabales, acquisition indebtedness and other liabilities)	2011-06-30	$0
Total income from all sources (including contributions)	2011-06-30	$119,902
Total loss/gain on sale of assets	2011-06-30	$0
Total of all expenses incurred	2011-06-30	$3,784
Benefit payments and payments to participlants,beneficiaries,insurance carriers and others	2011-06-30	$886
Value of total corrective distributions	2011-06-30	$0
Total contributions o plan (from employers,participants, others, non cash contrinutions)	2011-06-30	$99,189
Value of total assets at end of year	2011-06-30	$277,876
Value of total assets at beginning of year	2011-06-30	$161,758
Total of administrative expenses incurred including professional, contract, advisory and management fees	2011-06-30	$2,898
Total interest from all sources	2011-06-30	$0
Total dividends received (eg from common stock, registered investment company shares)	2011-06-30	$468
Has a resolution to terminate the plan been adopted during the plan year or any prior plan year	2011-06-30	No
Total dividends received from registered investment company shares (eg mutual funds)	2011-06-30	$468
Was this plan covered by a fidelity bond	2011-06-30	Yes
Value of fidelity bond cover	2011-06-30	$1,000,000
If this is an individual account plan, was there a blackout period	2011-06-30	No
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2011-06-30	$0
Were there any nonexempt tranactions with any party-in-interest	2011-06-30	No
Contributions received from participants	2011-06-30	$86,687
Income. Received or receivable in cash from other sources (including rollovers)	2011-06-30	$0
Other income not declared elsewhere	2011-06-30	$358
Administrative expenses (other) incurred	2011-06-30	$2,898
Did the receive any noncash contributions whose value was neither redily determinable on an established market nor set by an independent third party appraiser	2011-06-30	No
Value of net income/loss	2011-06-30	$116,118
Value of net assets at end of year (total assets less liabilities)	2011-06-30	$277,876
Value of net assets at beginning of year (total assets less liabilities)	2011-06-30	$161,758
Did the plan have a loss casued by fraud or dishonesty (regardless whether reimbursed by fidelity bond)	2011-06-30	No
Were any loans by the plan or fixed income obligations due to the plan in default	2011-06-30	No
Were any leases to which the plan was party in default or uncollectible	2011-06-30	No
Value of interest in registered invesment companies (eg mutual funds) at end of year	2011-06-30	$105,536
Value of interest in registered invesment companies (eg mutual funds) at beginning of year	2011-06-30	$49,546
Interest on participant loans	2011-06-30	$0
Value of interest in common/collective trusts at end of year	2011-06-30	$172,340
Value of interest in common/collective trusts at beginning of year	2011-06-30	$112,212
Net investment gain/loss from registered investment companies (e.g. mutual funds)	2011-06-30	$15,783
Net investment gain or loss from common/collective trusts	2011-06-30	$4,104
Were any plan transactions or series of transactions in excess of 5% of the current value of the plan assets	2011-06-30	No
Was there a failure to transmit to the plan any participant contributions	2011-06-30	No
Has the plan failed to provide any benefit when due under the plan	2011-06-30	No
Contributions received in cash from employer	2011-06-30	$12,502
Benefit payments and payments to provide benefits directly to participlants or beneficiaries including direct rollovers	2011-06-30	$886
Was the provided the required notice or one of the exceptions to providing the black out period notice applied under 29 CFR 2520.101-3	2011-06-30	No
Did the plan have assets held for investment	2011-06-30	Yes
Did the plan hold any assets whose current value was neither redily determinable on an established market nor set by an independent third party appraiser	2011-06-30	No
Were all the plan assets eitehr distributed to particpants/beneficiaries, transferred to another plan or brought under the control of the PBGC	2011-06-30	No
Accountant perfomed limited scope audit pursuant to 29 CFR 2520.103-8 and/or 103-12(d)	2011-06-30	Yes
Opinion of an independent qualified public accountant for this plan	2011-06-30	Disclaimer
Accountancy firm name	2011-06-30	RAICHE ENDE MALTOR & CO LLP
Accountancy firm EIN	2011-06-30	112336434
2010 : BACTOLAC PHARMACEUTICAL 401(K) PLAN 2010 401k financial data
Total value of distributions paid in property other than in cash, annuity contracts, or publicly traded employer securities	2010-06-30	$0

Form 5500 Responses for BACTOLAC PHARMACEUTICAL 401(K) PLAN

2021: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2021 form 5500 responses
2021-07-01	Type of plan entity	Single employer plan
2021-07-01	Submission has been amended	No
2021-07-01	This submission is the final filing	No
2021-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2021-07-01	Plan is a collectively bargained plan	No
2021-07-01	Plan funding arrangement – Insurance	Yes
2021-07-01	Plan funding arrangement – Trust	Yes
2021-07-01	Plan benefit arrangement – Insurance	Yes
2021-07-01	Plan benefit arrangement - Trust	Yes
2020: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2020 form 5500 responses
2020-07-01	Type of plan entity	Single employer plan
2020-07-01	Submission has been amended	No
2020-07-01	This submission is the final filing	No
2020-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2020-07-01	Plan is a collectively bargained plan	No
2020-07-01	Plan funding arrangement – Insurance	Yes
2020-07-01	Plan funding arrangement – Trust	Yes
2020-07-01	Plan benefit arrangement – Insurance	Yes
2020-07-01	Plan benefit arrangement - Trust	Yes
2019: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2019 form 5500 responses
2019-07-01	Type of plan entity	Single employer plan
2019-07-01	This submission is the final filing	No
2019-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2019-07-01	Plan funding arrangement – Trust	Yes
2019-07-01	Plan benefit arrangement - Trust	Yes
2018: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2018 form 5500 responses
2018-07-01	Type of plan entity	Single employer plan
2018-07-01	Submission has been amended	No
2018-07-01	This submission is the final filing	No
2018-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2018-07-01	Plan is a collectively bargained plan	No
2018-07-01	Plan funding arrangement – Trust	Yes
2018-07-01	Plan benefit arrangement - Trust	Yes
2017: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2017 form 5500 responses
2017-07-01	Type of plan entity	Single employer plan
2017-07-01	Submission has been amended	No
2017-07-01	This submission is the final filing	No
2017-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2017-07-01	Plan is a collectively bargained plan	No
2017-07-01	Plan funding arrangement – Trust	Yes
2017-07-01	Plan benefit arrangement - Trust	Yes
2016: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2016 form 5500 responses
2016-07-01	Type of plan entity	Single employer plan
2016-07-01	Submission has been amended	No
2016-07-01	This submission is the final filing	No
2016-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2016-07-01	Plan is a collectively bargained plan	No
2016-07-01	Plan funding arrangement – Trust	Yes
2016-07-01	Plan benefit arrangement - Trust	Yes
2015: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2015 form 5500 responses
2015-07-01	Type of plan entity	Single employer plan
2015-07-01	Submission has been amended	No
2015-07-01	This submission is the final filing	No
2015-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2015-07-01	Plan is a collectively bargained plan	No
2015-07-01	Plan funding arrangement – Trust	Yes
2015-07-01	Plan benefit arrangement - Trust	Yes
2014: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2014 form 5500 responses
2014-07-01	Type of plan entity	Single employer plan
2014-07-01	Submission has been amended	No
2014-07-01	This submission is the final filing	No
2014-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2014-07-01	Plan is a collectively bargained plan	No
2014-07-01	Plan funding arrangement – Trust	Yes
2014-07-01	Plan benefit arrangement - Trust	Yes
2013: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2013 form 5500 responses
2013-07-01	Type of plan entity	Single employer plan
2013-07-01	Submission has been amended	No
2013-07-01	This submission is the final filing	No
2013-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2013-07-01	Plan is a collectively bargained plan	No
2013-07-01	Plan funding arrangement – Trust	Yes
2013-07-01	Plan benefit arrangement - Trust	Yes
2012: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2012 form 5500 responses
2012-07-01	Type of plan entity	Single employer plan
2012-07-01	Submission has been amended	No
2012-07-01	This submission is the final filing	No
2012-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2012-07-01	Plan is a collectively bargained plan	No
2012-07-01	Plan funding arrangement – Trust	Yes
2012-07-01	Plan benefit arrangement - Trust	Yes
2011: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2011 form 5500 responses
2011-07-01	Type of plan entity	Single employer plan
2011-07-01	Submission has been amended	Yes
2011-07-01	This submission is the final filing	No
2011-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2011-07-01	Plan is a collectively bargained plan	No
2011-07-01	Plan funding arrangement – Trust	Yes
2011-07-01	Plan benefit arrangement - Trust	Yes
2010: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2010 form 5500 responses
2010-07-01	Type of plan entity	Single employer plan
2010-07-01	Submission has been amended	No
2010-07-01	This submission is the final filing	No
2010-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2010-07-01	Plan is a collectively bargained plan	No
2010-07-01	Plan funding arrangement – Trust	Yes
2010-07-01	Plan benefit arrangement - Trust	Yes
2009: BACTOLAC PHARMACEUTICAL 401(K) PLAN 2009 form 5500 responses
2009-07-01	Type of plan entity	Single employer plan
2009-07-01	Submission has been amended	No
2009-07-01	This submission is the final filing	No
2009-07-01	This return/report is a short plan year return/report (less than 12 months)	No
2009-07-01	Plan is a collectively bargained plan	No
2009-07-01	Plan funding arrangement – Trust	Yes
2009-07-01	Plan benefit arrangement - Trust	Yes

Insurance Providers Used on plan

THE LINCOLN NATIONAL LIFE INSURANCE COMPANY (National Association of Insurance Commissioners NAIC id number: 65676 )

Policy contract number

896680 087

Policy instance

Insurance contract or identification number	896680 087
Number of Individuals Covered	15
Insurance policy start date	2021-07-01
Insurance policy end date	2022-06-30
Contract purchased, in whole or in part, to distribute benefits from a terminating plan	No
Contracts With Unallocated Funds Deposit Administration	0
Are there contracts with unallocated funds for contracts of type immediate participation guarantee?	No
Are there contracts with unallocated funds for contracts of type guaranteed investment?	Yes
Are there contracts with unallocated funds for contract types other than deposit administration, immediate participation guarantee or guaranteed investment?	No
Health Insurance Welfare Benefit	No
Dental Insurance Welfare Benefit	No
Vision Insurance Welfare Benefit	No
Life Insurance Welfare Benefit	No
Temporary Disability Insurance Welfare Benefit	No
Long Term Disability Insurance Welfare Benefit	No
Unemployment Insurance Welfare Benefit	No
Did the insurance company fail to provide any information necessary to complete Schedule A of form 5500?	No

THE LINCOLN NATIONAL LIFE INSURANCE COMPANY (National Association of Insurance Commissioners NAIC id number: 65676 )

Policy contract number

896680 087

Policy instance

Insurance contract or identification number	896680 087
Number of Individuals Covered	16
Insurance policy start date	2021-02-01
Insurance policy end date	2021-06-30
Total amount of commissions paid to insurance broker	USD $0
Total amount of fees paid to insurance company	USD $0
Are there contracts with allocated funds for individual policies?	0
Are there contracts with allocated funds for types other than group deferred annuity or individual?	No
Contracts With Unallocated Funds Deposit Administration	0
Are there contracts with unallocated funds for contracts of type immediate participation guarantee?	No
Are there contracts with unallocated funds for contracts of type guaranteed investment?	Yes
Are there contracts with unallocated funds for contract types other than deposit administration, immediate participation guarantee or guaranteed investment?	No
Health Insurance Welfare Benefit	No
Dental Insurance Welfare Benefit	No
Vision Insurance Welfare Benefit	No
Life Insurance Welfare Benefit	No
Temporary Disability Insurance Welfare Benefit	No
Long Term Disability Insurance Welfare Benefit	No
Unemployment Insurance Welfare Benefit	No
Were dividends or retroactive rate refunds paid in cash?	No
Were dividends or retroactive rate refunds paid as a credit?	No
Did the insurance company fail to provide any information necessary to complete Schedule A of form 5500?	No

Was this data useful?

If you found the data here useful, PLEASE HELP US. We are a start-up and believe in making information freely available. By linking to us, posting on twitter, facebook and linkedin about us and generally spreading the word, you'll help us to grow. Our vision is to provide high quality data about the activities of all the companies in the world and where possible make it free to use and view. Finding and integrating data from thousands of data sources is time consuming and needs lots of effort. By simply spreading the word about us, you will help us. Please use the share buttons. It will only take a few seconds of your time. Thanks for helping

Information Disclaimer

The information provided on this website is not advice, endorsement or recommendation
The information published is supplied by third parties so we make no warranty on the accuracy, completeness etc. This information is provided "as-is". The information is subject to change as we obtain updates and corrections from the primary information sources.
You are free to use the information for your own personal research on the understanding to do so is at your own risk.

See full terms and conditions

Company Name:	BACTOLAC PHARMACEUTICAL, INC.
Employer identification number (EIN):	113259533
NAIC Classification:	325410

Jurisdiction of Incorporation:	State of Delaware Division of Corporations
Incorporation Date:
Company Identification Number:	2929493